John G. Babish, et al.
U.S.S.N. 10/774,048
AMENDMENT and REQUEST FOR RECONSIDERATION UNDER 37 C.F.R § 1.116
November 20, 2006
Page 2 of 9

AMENDMENT TO THE CLAIMS

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.

Please amend the claims as shown below:

- 1. (Currently Amended) A composition comprising a fraction isolated or derived from hops selected from the group consisting of reduced isoalpha acids, dihydro-isolalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids, and a non-aspirin, non-steroidal anti-inflammatory compound.
- 2. (Canceled) The composition of claim 1, wherein the fraction isolated or derived from hops is selected from the group consisting of alpha acids, isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids, and spent hops.
- 3. (Currently Amended) The composition of claim 1, wherein the said fraction isolated or derived from hops comprises a compound <u>selected from the group consisting of reduced isoalpha acids</u>, dihydro-isolalpha acids, tetra-hydroisoalpha acids, and hexa-hydroisoalpha acids of a supragenus having the formula:

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

wherein R" is selected from the group consisting of CH(CH₃)₂, CH₂CH(CH₃)₂, and CH(CH₃)CH₂CH₃;

and wherein R, T, X, and Z are independently selected from the group consisting of H, F, Cl, Br, I, and π orbital, with the proviso that if one of R, T, X, or Z is a π orbital, then the adjacent R, T, X, or Z is also a π orbital, thereby forming a double bond.

BST99 1523713-1.068911.0062

AMENDMENT and REQUEST FOR RECONSIDERATION UNDER 37 C.F.R § 1.116

November 20, 2006

Page 3 of 9

4. (Currently Amended) The composition of claim 1, wherein said fraction isolated or derived from hops comprises a <u>reduced</u> isoalpha acid compound of Genus A having the formula:

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R" is selected from the group consisting of $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, and $CH(CH_3)CH_2CH_3$.

5. (Currently Amended) The composition of claim 1, wherein the fraction isolated or derived from hops comprises a <u>tetra-hydroisoalpha acid or a hexa-hydroisoalpha acid</u> compound of Genus B having the formula:

wherein R' is selected from the group consisting of carbonyl, hydroxyl, OR, and OCOR, wherein R is alkyl;

and wherein R" is selected from the group consisting of $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, and $CH(CH_3)CH_2CH_3$.

John G. Babish, et al. U.S.S.N. 10/774,048

AMENDMENT and REQUEST FOR RECONSIDERATION UNDER 37 C.F.R § 1.116

November 20, 2006

Page 4 of 9

- 6. (Currently Amended) The composition of claim 1, wherein said fraction isolated or derived from hops comprises a compound selected from the group consisting of humulone, cohumulone, adhumulone, isocohumulone, isocohumulone, dihydro-isochumulone, dihydro-isochumulone, tetrahydro-isochumulone, tetrahydro-isocohumulone, tetrahydro-isocohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.
- 7. (Currently Amended) The composition of claim 1, wherein the composition comprises about 0.5 to 10,000 mg of said fraction isolated or derived from hops.
- 8. (Currently Amended) The composition of claim 7, wherein the composition comprises about 50 to 7,500 mg of the fraction isolated or derived from hops.
- 9. (Original) The composition of claim 1, wherein the composition comprises about 0.001 to 10 weight percent of the fraction isolated or derived from hops.
- 10. (Original) The composition of claim 9, wherein the composition comprises about 0.1 to 1 weight percent of the fraction isolated or derived from hops.
- 11. (Original) The composition of claim 1, wherein the non-aspirin, nonsteroidal anti-inflammatory compound is selected from the group consisting of salicylic acid, methyl salicylate, difulunisal, salsalate, olsalazine, sulfasalazine, acetanilide, acetaminophen, phenacetin, mefenamic acid, sodium meclofenamate, tolmetin, ketorolac, diclofenac, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbioprofen, oxaprozin, piroxicam, meloxicam, tenoxicam, ampiroxicam, droxicam, pivoxicam, phenylbutazone, oxyphenbutazone, anitpyrine, aminopyrine, dipyrone, celecoxib, rofecoxib, nabumetone, apazone, nimensulide, indomethacin, sulindac, and etodolac.
- 12. (Previously Amended) The composition of claim 1, wherein the non-aspirin, nonsteroidal anti-inflammatory is selected from the group consisting of salicylic acid, methyl salicylate, ibuprofen, naproxen, sodium daproxen, fenoprofen, ketoprofen, flurbioprofen, and oxaprozin.

John G. Babish, et al.
U.S.S.N. 10/774,048
AMENDMENT and REQUEST FOR RECONSIDERATION UNDER 37 C.F.R § 1.116
November 20, 2006
Page 5 of 9

- 13. (Original) The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
- 14. (Original) The composition of claim 1, wherein the composition is formulated for administration orally, topically, parenterally, or rectally.
- 15. (Original) A composition comprising a reduced isoalpha acid isolated from hops and a non-steroidal anti-inflammatory compound.
- 16. (Original) The composition of claim 15, wherein the reduced isoalpha acid is selected from dihydro-isohumulone, dihydro-isocohumulone, and dihydro-adhumulone.

Claims 17-36 (Previously Canceled).